Current and Prospective Treatment Options for Waldenström Macroglobulinemia
Researchers discussed diagnostic considerations, indications for therapy, and treatment options for patients with Waldenström macroglobulinemia.
Lymphoma
LYMPHOMA
FEATURE
LATEST NEWS
Real-World Data Back Efficacy of Axi-Cel in R/R DLBCL
Even among those with more comorbidities, safety, efficacy of treatment remained.
Oxaliplatin May Reduce Nephrotoxicity Compared With Cisplatin in B-Cell Lymphoma
Researchers compared the efficacy and nephrotoxicity of R-DHAP vs R-DHAOx among patients treated for NHL between 2007 and 2014.
Evaluation of Primary Cardiac Lymphoma Incidence and Prognosis Using SEER Database
SEER analysis reveals age, Ann Arbor stage, and chemotherapy as critical factors affecting prognosis in patients with primary cardiac lymphoma.
Nivolumab Is Promising as First-Line Treatment for Unfavorable Classic Hodgkin Lymphoma
Nivolumab-based first-line treatment may result in high remission and progression-free survival rates in early-stage unfavorable classic Hodgkin lymphoma.
Hypercalcemia as a Biomarker for Biological Aggressiveness of Diffuse Large B-Cell Lymphoma
Hypercalcemia is not uncommon in patients with de novo diffuse large B-cell lymphoma and may be linked to a higher risk for other adverse events.
Review of Features, Treatment Options in Peripheral T-Cell Lymphoma
Combined targeted agents with immune regulators and chimeric antigen receptor cell–based therapies may improve overall survival for patients with PTCL.
DNA Repair Gene-Related CHIP Is a Marker for Worse Outcomes in Patients With Lymphoma
Clonal hematopoiesis of indeterminate origin has been defined as the presence of somatic mutations in hematopoietic stem cells at a variant gene frequency of more than 2%.
Requirements for Better Outcomes for Patients With Non-Hodgkin Lymphoma in Sub-Saharan Africa
Researchers oulined changes in diagnostics, surveillance, and treatment practices that could lead to better outcomes for patients with NHL in sub-Saharan Africa.
Dose-Adjusted EPOCH for B-Cell Lymphomas May Be Safe, Cost Effective in the Outpatient Setting
Researchers found that dose-adjusted (DA-) etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (EPOCH) for B-cell lymphomas can be administered safely in the outpatient setting and that outpatient administration was associated with significant savings relative to inpatient administration. Wenhui Li, PharmD, of the H. Lee Moffitt Cancer Center in Tampa, Florida, and colleagues published their findings in…
Age, Performance Status Linked With Failure to Complete R-CHOP in Diffuse Large B-Cell Lymphoma
There is clinical and real-world evidence that indicates some patients do not complete treatment for reasons other than lack of response.
Molecular Determinants of Venetoclax Response in Acute Myeloid Leukemia Identified
Patients with a NPM1, IDH1, IDH2, or DNMT3A mutation had a complete response or complete response with incomplete hematologic recovery rate of more than 80%.
Copanlisib: Safe, Effective in Relapsed or Refractory B Cell Lymphoma
Researchers conducted a 2-year safety and efficacy follow-up analysis to determine whether long-term data support the initial toxicity findings.
Lymphoid Malignancies: Novel Transplantations Are Improving Outcomes
While HLA-identical sibling or unrelated donors were previously critical for successful transplantation, increased genomic heterogeneity across populations have heightened the need for alternatives.
Induction in Transplant-Eligible Mantle Cell Lymphoma With Rituximab and Cytarabine Added to Rituximab and Bendamustine
The researchers found that high rates of remission could be achieved with induction therapy using rituximab/bendamustine in addition to rituximab/cytarabine.
Brentuximab Vedotin With Bendamustine for Patients With Refractory or Multiple Relapsed Classic Hodgkin Lymphoma
A retrospective analysis found encouraging evidence for the use of BvB in treatment of RR-cHL.
Glyphosate Exposure and Relative Risks of Non-Hodgkin Lymphoma or Multiple Myeloma
Researchers conducted a meta-analysis of 7 studies involving NHL and 3 focused on MM to determine the role of occupational exposure to glyphosate in terms of risk.
Elevated Risk for Cause-Specific Mortality in Waldenström Macroglobulinemia
Patients with LPL or WM had a 30% increased risk for death due to noncancer causes compared with the general population.
Rituximab Failure Predicts Poor Outcome in DLBCL-Resembling Post-Transplant Lymphoproliferative Disorder
Stable disease or progression compared with complete response was found to be predictive of overall survival in patients receiving rituximab-primary treatment.
Phase 1 Trial Outcomes With Urelumab in Relapsed or Refractory B-Cell Lymphoma
Half of responses with urelumab monotherapy were found to occur at a dosage above the maximum tolerated dose.
Clinical Response to Tisagenlecleucel Confers HRQoL Benefit in Lymphoma
Patients with relapsed/refractory diffuse large B-cell lymphoma who responded to tisagenlecleucel also had improved health-related quality of life outcomes.
No Change in Transplant Outcomes for DLBCL With Addition of Rituximab to Conditioning
Overall survival, progression-free survival, and nonrelapse mortality were found to be similar in patients receiving BEAM conditioning with or without rituximab.
Intensive Immunochemotherapy May Yield Positive Outcomes in Burkitt Lymphoma
Researchers assessed data from Australian population-based lymphoma registries to determine the efficacy of intensive immunochemotherapy for Burkitt lymphoma.
Best Practices for Diagnosing Breast Implant-Associated Anaplastic Large Cell Lymphoma
In 2016, the World Health Organization classified BIA-ALCL as a novel lymphoma.
Priority Review Granted to Tazemetostat for Follicular Lymphoma Indication
The Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for Tazverik® (tazemetostat; Epizyme) for the treatment of patients with relapsed or refractory follicular lymphoma (FL) who have received at least 2 prior lines of systemic therapy.
Comparing Cost-Effectiveness of First-Line Treatment Approaches for Hodgkin Lymphoma
Of 5 treatment regimens assessed, a PET-adapted de-escalation treatment approach was found to be the most cost-effective in 87% of cases modelled.
Prognostic Factors for Patients Undergoing Autologous Stem Cell Transplant for DLBCL
Researchers assessed potential differences in transplant outcomes in Japan before and after the era that introduced rituximab treatment.
Brentuximab Vedotin May Improve Survival in Stage III/IV Classical Hodgkin Lymphoma
Patients who received treatment with brentuximab vedotin experienced improved progression-free survival.
Pixantrone or Gemcitabine and Rituximab for Relapsed, Aggressive B-Cell Non-Hodgkin Lymphoma
Patients receiving pixantrone plus rituximab and patients receiving gemcitabine plus rituximab experienced similar progression-free survival.
Younger Age, Consolidation Therapy With Autologous SCT Associated With Improved OS in Patients With Primary CNS Lymphoma
Despite improvements in treatment of CNS lymphoma, median age of people who develop the disease is increasing. Nearly three-quarters of patients included in this population-based study were 60 years or older.
Deepened Responses in Waldenström Macroglobulinemia After Rituximab
A deepened response following therapy with a regimen containing rituximab was associated with improved progression-free survival.
Bendamustine Improves Event-Free Survival in Elderly Patients With Indolent B-Cell Lymphomas
Bendamustine-based first-line chemotherapy was associated with fewer hospitalizations and fewer toxic events compared with cyclophosphamide-based regimens.
Long-Term Follow-Up of R-CHOP and Rituximab Maintenance in Elderly Patients With Mantle Cell Lymphoma
Long-term follow-up confirmed preliminary results suggesting that rituximab maintenance following treatment with R-CHOP is safe and effective.
Reduced‐Intensity Conditioning May Improve Survival in Relapsed/Refractory Anaplastic Large Cell Lymphoma
Overall survival at 5 years was 100% with the reduced-intensity conditioning regimen compared with 48.5% with the myeloablative conditioning regimen.
Older Patients With Follicular Lymphoma Benefit From Appropriate Therapy
For older patients with follicular lymphoma, receipt of appropriate therapy for this disease was associated with a significant gain in overall survival.
Real-World Outcomes With Ibrutinib in Waldenström Macroglobulinemia
A study of real-world patients with Waldenström macroglobulinemia revealed that ibrutinib monotherapy was linked to efficacy — but also toxicity.
Health-Related Quality of Life Unchanged With Lenalidomide Maintenance for DLBCL
Progression-free survival was superior with lenalidomide compared with placebo, while health-related quality of life was similar and did not change during the study.
Immunoglobulin Replacement May Benefit Some Patients Receiving CAR-T Therapy
CAR-T therapy can sometimes lead to immune system dysfunction, subsequent hypogammaglobulinemia, and the need for antibody replacement therapy.
High Use of Oncology Nurse Navigators Showed Similar Clinical Outcomes for White, Nonwhite Patients with DLBCL
Although previous population-based studies have shown worse clinical outcomes for minority patients with DLBCL compared with white patients, this study reported no differences in PFS and OS were seen between the 2 groups.
Concomitant Diseases May Significantly Affect Outcomes in Patients With Mantle Cell Lymphoma
Severe comorbidities were found to be associated with increased all-cause and lymphoma-specific mortality compared with patients without comorbidities.
Treatment Characteristics and Outcomes for Patients With Rare Forms of T-Cell Lymphoma
Researchers characterized outcomes for enteropathy-associated T-cell lymphoma, hepatosplenic T-cell lymphoma, and peripheral gamma delta T-cell lymphoma.
Treatment Strategies for Lymphoma in Patients With HIV
Cancer, particularly non-Hodgkin lymphoma, remains a leading cause of death in patients with HIV who are being treated with antiretroviral therapy.
Polatuzumab Vedotin for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
In phase 2 analyses, patients receiving polatuzumab vedotin experienced improved overall and progression-free survival compared with patients in the control arm.
Influence of Facility Patient Volume on Mortality in Classical Hodgkin Lymphoma
Facilities that treated more patients with classical Hodgkin lymphoma annually had lower overall mortality rates.
Trace Metal Concentrations in Specimens of Patients With Lymphoma
This study used atomic absorption spectrometry to evaluate the levels of trace metals in specimens of patients with lymphoma compared with healthy controls.
Pretreatment Vitamin D Deficiency Associated With Outcomes in Hodgkin Lymphoma
Patients with Hodgkin lymphoma who were deficient for vitamin D experienced reduced progression-free and overall survival.
Imaging Mass Cytometry Reveals Prognostic Immune Phenotypes in DLBCL
Imaging mass cytometry can characterize the spatial landscape of different types of immune cells in the tumor microenvironment of tissue specimens.
Durvalumab Adds No Benefit to Single-Agent Ibrutinib in FL, DLBCL
The combination warrants no further study in these patients.
FDA Grants Accelerated Approval to Brukinsa for Mantle Cell Lymphoma
Continued approval may be contingent upon verification of clinical benefit in a confirmatory trial.
Even Slight Delays in CAR-T Therapy Administration May Increase Overall Mortality Rates
Researchers created a discrete event simulation model to assess the potential influence of wait time ranging from 1 to 9 months on CAR-T therapy efficacy.
Gastrointestinal Involvement May Be a Sign of Waldenström Macroglobulinemia
Gastrointestinal-tract involvement may be a comorbid condition in patients with Waldenström macroglobulinemia.
Want to read more?
Please login or register first to view this content.
Next post in Lymphoma
